Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisoprolol for Prevention of Anthracycline-induced Cardiotoxicity
NCT05175066Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bisoprolol in anthracycline-induced cardiotoxicity, sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Left Ventricular Ejection Fraction at 6 months and Global Longitudinal Strain at 6 months. Started Nov 2020; status: completed.
02
Drugs
bisoprolol
03
Conditions
anthracycline-induced cardiotoxicity
Beyond the preview
Go deeper on NCT05175066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175066.